

Abstract

The present invention provides a compound represented by general formula [1] and having a DDR1 kinase inhibitory activity, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt (in the formula, R¹ represents a hydrogen atom, a halogen atom, or an optionally substituted alkyl group; Het represents a 5- to 10-membered heteroaryl group; L¹ represents -CO-NH- or -CR^a=CR^b-; X represents C-R^c; R² represents a C₁-C₆ haloalkoxy group or a C₁-C₆ haloalkyl group; R³, R⁴ and carbon atoms to which these residues are bound together form an optionally substituted C₃-C₆ cycloalkyl group or an optionally substituted heterocycloalkyl group).

